Gene Expression Market By Products (Consumable, Instruments), By Application (Drug Discovery, Diagnostics), By End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031

Gene Expression Market

Gene expression is an important life process through which gene sequences are transcribed into functional gene products such as functional RNAs or proteins. It plays an important role in functioning and development of an organism and provides a connection between gene-encoded information and a functional gene end-product. It is determined by deciphering the gene information during the transcription and translation process and is very useful in identifying the molecular signature of a disease and for determining biomarker in correlation with dose dependent cellular responses on exposure to drug or therapeutic candidate. 

Key factors driving the growth of the gene expression market include the increase in the prevalence of genetic disorders, growing application of gene expression in drug discovery and rise in the demand of personalized medicine for genetic disorders. A mutation in a gene that codes for a protein involved in a metabolic pathway can lead to a metabolic disorder, such as cystic fibrosis or phenylketonuria. In addition, changes in gene expression can cause abnormal development of organs and tissues, resulting in birth defects. By understanding how gene expression works, scientists can identify potential treatments for genetic disorders, such as gene therapy and targeted drug therapy. Thus, the rise in the prevalence of rare genetic disorder increases the demand for gene therapy that boost the growth of the market. For instance, according to the report published by Centers for Disease Control and Prevention, in December 2022 it has been estimated that chromosomal defect affected 531 babies with trisomy 13 (Patau syndrome) which is 1 in every 7,409 births, 1,187 babies were affected by trisomy 18 (Edwards syndrome), and 5,568 babies acquired trisomy 21 (Down syndrome) in U.S. Thus, the increasing incidence of rare genetic and chromosomal disorder is anticipated to increase the demand for gene expression therapy, thereby driving the growth of the market. The increase in the demand for personalized medicine is driving the growth of the gene expression market. Personalized medicine is an approach to healthcare that uses genetic information to identify the most effective treatments for a person's particular genetic make-up. Thus, with the help of gene expression data, physician can better understand the patient's individual risks and vulnerabilities and tailor treatments more specifically to their needs. This increases the demand for gene expression technologies and services, particularly in the area of diagnostics that propels the growth of the market. In addition, the rise in the development of new technologies and techniques such as high-throughput sequencing and next-generation sequencing is increasing the accuracy and speed of gene expression analysis, leading to more precise diagnoses. These are the major factors that propel the growth of the market over the forecast period. 

The market also offers growth opportunities to the key players in the market. The rise in prevalence of genetic disorders and cancers in developing nations (such as Brazil, India, and China) will increase the demand for personalized medicine is anticipated to provide lucrative growth opportunities for the market. For instance, according to the report published in MedlinePlus, in 2021, it has been estimated that, about 1 in 200,000 people in the U.S. are diagnosed with gene variant syndrome each year. Whereas, an estimated 15,000 people worldwide were diagnosed with genetic disease last year. In addition, approximately 1 in 100,000 people in the U.S. have genetic disorders at the present time. About 100,000 children worldwide currently have genetic disorders. Moreover, the surge in geriatric populations and increasing advancements in genomics and technological developments in gene expression techniques are the factors that propel the market growth in the upcoming years. Furthermore, the emerging nations need to focus on the adoption of the latest technologies for gene expression that are crucial to treat the genetic disorders. Therefore, technological advancements and rising awareness among people toward rising prevalence of genetic disorder and the availability of gene expression-based instruments and reagents to cure the disease offer lucrative opportunities for the growth of the gene expression market. 

The gene expression market is segmented on the basis of product, application, end-user, and region. By product, the market is segmented into consumables and instruments. The instruments are further bifurcated into polymerase chain reaction, next generation sequencing, and DNA microarrays and others. As per application, the market is bifurcated into drug discovery and diagnostics. According to end user, it is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.    

The key players that operate in the gene expression market are Illumina Inc., Agilent Technologies, Thermo Fisher Scientific Inc., PerkinElmer Inc., Oxford Nanopore Technologies, QIAGEN, Bio-Rad Laboratories Inc., PacBio, Promega Corporation, and F. Hoffmann-La Roche Ltd. 

Key Market Insights 

By product, the consumables segment is expected to experience rapid growth in the market and is estimated to reach $9,540.82 million by 2031, with a CAGR of 8.0%. However, the instruments segment is estimated to be growing with a significant CAGR of 7.3% during the forecast period. 

By application, the diagnostics segment dominated the global market. However, the drug discovery segment is expected to grow with a significant CAGR of 7.2% during the forecast period. 

By end user, the pharmaceutical & biotechnology companies segment dominated the global market. However, the academic research & institutes segment is expected to grow with a significant CAGR of 7.9% during the forecast period. 

Based on region, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR of 9.1% during the forecast period. 

Overview

The gene expression market valued for $8,505.71 million in 2021 and is estimated to reach $17,960.77 million by 2031, exhibiting a CAGR of 7.7% from 2022 to 2031. Gene expression is the process by which the information encoded in a gene is turned into a function. This mostly occurs via the transcription of RNA molecules that code for proteins or non-coding RNA molecules that serve other functions. Gene expression can be thought of as an “on/off switch” to control when and where RNA molecules and proteins are made and as a “volume control” to determine how much of those products are made.   

The key factors that drive the growth of the gene expression market is the rising demand for personalized medicine and technological advancement in genomics such as next-generation sequencing and CRISPR technology that have enabled the development of gene expression products with higher precision and accuracy. For instance, in March 2021 Thermo Fisher Scientific announced the completion of the U.S. Food and Drug Administration (FDA) listing for the applied biosystems QuantStudio 5 Dx Real-Time PCR System. The QuantStudio 5 is a comprehensive gene expression platform designed to provide high-throughput gene expression data on the go. This innovative product enables clinical laboratories and assay developers to meet testing demands and enhance molecular diagnostics workflows. Thus, the rise in the prevalence of chronic disease, and development of technologically advanced solutions is anticipated to boost the growth of the market.   

However, the high cost of instruments for gene expression and lack of skilled professional hampers the market growth. Conversely, increased investments in R&D for the development of new technologies for tissue-specific or cell-specific gene expression analysis, as well as increase in the prevalence of chronic and genetic diseases may open up the new market potential for gene expression and are expected to provide a lucrative opportunity for the growth of the market during the forecast period.     

The gene expression market is segmented on the basis of product, application, end-user, and region. By product, the market is segmented into consumables and instruments. The instruments are further bifurcated into polymerase chain reaction, next generation sequencing, and DNA microarrays and others. As per application, the market is bifurcated into drug discovery and diagnostics. According to end user, it is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.    

The key players that operate in the gene expression market are Illumina Inc., Agilent Technologies, Thermo Fisher Scientific Inc., PerkinElmer Inc., Oxford Nanopore Technologies, QIAGEN, Bio-Rad Laboratories Inc., PacBio, Promega Corporation, and F. Hoffmann-La Roche Ltd.

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the gene expression market analysis from 2021 to 2031 to identify the prevailing gene expression market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the gene expression market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global gene expression market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

○ Promega Corporatio

Scope of Gene Expression Market Report

1.1. Report description

1.2. Key market segments

1.3. Key benefits to the stakeholders

1.4. Research Methodology

1.4.1. Primary research

1.4.2. Secondary research

1.4.3. Analyst tools and models

2.1. CXO Perspective

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top impacting factors

3.2.2. Top investment pockets

3.3. Porter’s five forces analysis

3.3.1. Bargaining power of suppliers

3.3.2. Bargaining power of buyers

3.3.3. Threat of substitutes

3.3.4. Threat of new entrants

3.3.5. Intensity of rivalry

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Increase in the prevalence of genetic disorders.

3.4.1.2. Growing application of gene expression in drug discovery

3.4.1.3. Rise in the demand of personalized medicine for genetic disorders

3.4.2. Restraints

3.4.2.1. High cost of gene expression instruments & reagents

3.4.2.2. Lack of skilled professionals

3.4.3. Opportunities

3.4.3.1. High growth potential in developing economies

3.5. COVID-19 Impact Analysis on the market

4.1. Overview

4.1.1. Market size and forecast

4.2. Consumable

4.2.1. Key market trends, growth factors and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market share analysis by country

4.3. Instruments

4.3.1. Key market trends, growth factors and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market share analysis by country

4.3.4. Instruments Gene Expression Market by Type

5.1. Overview

5.1.1. Market size and forecast

5.2. Drug Discovery

5.2.1. Key market trends, growth factors and opportunities

5.2.2. Market size and forecast, by region

5.2.3. Market share analysis by country

5.3. Diagnostics

5.3.1. Key market trends, growth factors and opportunities

5.3.2. Market size and forecast, by region

5.3.3. Market share analysis by country

6.1. Overview

6.1.1. Market size and forecast

6.2. Pharmaceutical and Biotechnology Companies

6.2.1. Key market trends, growth factors and opportunities

6.2.2. Market size and forecast, by region

6.2.3. Market share analysis by country

6.3. Academic and Research Institutes

6.3.1. Key market trends, growth factors and opportunities

6.3.2. Market size and forecast, by region

6.3.3. Market share analysis by country

6.4. Others

6.4.1. Key market trends, growth factors and opportunities

6.4.2. Market size and forecast, by region

6.4.3. Market share analysis by country

7.1. Overview

7.1.1. Market size and forecast By Region

7.2. North America

7.2.1. Key trends and opportunities

7.2.2. Market size and forecast, by Products

7.2.3. Market size and forecast, by Application

7.2.4. Market size and forecast, by End User

7.2.5. Market size and forecast, by country

7.2.5.1. U.S.

7.2.5.1.1. Key market trends, growth factors and opportunities

7.2.5.1.2. Market size and forecast, by Products

7.2.5.1.3. Market size and forecast, by Application

7.2.5.1.4. Market size and forecast, by End User

7.2.5.2. Canada

7.2.5.2.1. Key market trends, growth factors and opportunities

7.2.5.2.2. Market size and forecast, by Products

7.2.5.2.3. Market size and forecast, by Application

7.2.5.2.4. Market size and forecast, by End User

7.2.5.3. Mexico

7.2.5.3.1. Key market trends, growth factors and opportunities

7.2.5.3.2. Market size and forecast, by Products

7.2.5.3.3. Market size and forecast, by Application

7.2.5.3.4. Market size and forecast, by End User

7.3. Europe

7.3.1. Key trends and opportunities

7.3.2. Market size and forecast, by Products

7.3.3. Market size and forecast, by Application

7.3.4. Market size and forecast, by End User

7.3.5. Market size and forecast, by country

7.3.5.1. Germany

7.3.5.1.1. Key market trends, growth factors and opportunities

7.3.5.1.2. Market size and forecast, by Products

7.3.5.1.3. Market size and forecast, by Application

7.3.5.1.4. Market size and forecast, by End User

7.3.5.2. France

7.3.5.2.1. Key market trends, growth factors and opportunities

7.3.5.2.2. Market size and forecast, by Products

7.3.5.2.3. Market size and forecast, by Application

7.3.5.2.4. Market size and forecast, by End User

7.3.5.3. UK

7.3.5.3.1. Key market trends, growth factors and opportunities

7.3.5.3.2. Market size and forecast, by Products

7.3.5.3.3. Market size and forecast, by Application

7.3.5.3.4. Market size and forecast, by End User

7.3.5.4. Italy

7.3.5.4.1. Key market trends, growth factors and opportunities

7.3.5.4.2. Market size and forecast, by Products

7.3.5.4.3. Market size and forecast, by Application

7.3.5.4.4. Market size and forecast, by End User

7.3.5.5. Spain

7.3.5.5.1. Key market trends, growth factors and opportunities

7.3.5.5.2. Market size and forecast, by Products

7.3.5.5.3. Market size and forecast, by Application

7.3.5.5.4. Market size and forecast, by End User

7.3.5.6. Rest of Europe

7.3.5.6.1. Key market trends, growth factors and opportunities

7.3.5.6.2. Market size and forecast, by Products

7.3.5.6.3. Market size and forecast, by Application

7.3.5.6.4. Market size and forecast, by End User

7.4. Asia-Pacific

7.4.1. Key trends and opportunities

7.4.2. Market size and forecast, by Products

7.4.3. Market size and forecast, by Application

7.4.4. Market size and forecast, by End User

7.4.5. Market size and forecast, by country

7.4.5.1. Japan

7.4.5.1.1. Key market trends, growth factors and opportunities

7.4.5.1.2. Market size and forecast, by Products

7.4.5.1.3. Market size and forecast, by Application

7.4.5.1.4. Market size and forecast, by End User

7.4.5.2. China

7.4.5.2.1. Key market trends, growth factors and opportunities

7.4.5.2.2. Market size and forecast, by Products

7.4.5.2.3. Market size and forecast, by Application

7.4.5.2.4. Market size and forecast, by End User

7.4.5.3. Australia

7.4.5.3.1. Key market trends, growth factors and opportunities

7.4.5.3.2. Market size and forecast, by Products

7.4.5.3.3. Market size and forecast, by Application

7.4.5.3.4. Market size and forecast, by End User

7.4.5.4. India

7.4.5.4.1. Key market trends, growth factors and opportunities

7.4.5.4.2. Market size and forecast, by Products

7.4.5.4.3. Market size and forecast, by Application

7.4.5.4.4. Market size and forecast, by End User

7.4.5.5. South Korea

7.4.5.5.1. Key market trends, growth factors and opportunities

7.4.5.5.2. Market size and forecast, by Products

7.4.5.5.3. Market size and forecast, by Application

7.4.5.5.4. Market size and forecast, by End User

7.4.5.6. Rest of Asia-Pacific

7.4.5.6.1. Key market trends, growth factors and opportunities

7.4.5.6.2. Market size and forecast, by Products

7.4.5.6.3. Market size and forecast, by Application

7.4.5.6.4. Market size and forecast, by End User

7.5. LAMEA

7.5.1. Key trends and opportunities

7.5.2. Market size and forecast, by Products

7.5.3. Market size and forecast, by Application

7.5.4. Market size and forecast, by End User

7.5.5. Market size and forecast, by country

7.5.5.1. Brazil

7.5.5.1.1. Key market trends, growth factors and opportunities

7.5.5.1.2. Market size and forecast, by Products

7.5.5.1.3. Market size and forecast, by Application

7.5.5.1.4. Market size and forecast, by End User

7.5.5.2. Saudi Arabia

7.5.5.2.1. Key market trends, growth factors and opportunities

7.5.5.2.2. Market size and forecast, by Products

7.5.5.2.3. Market size and forecast, by Application

7.5.5.2.4. Market size and forecast, by End User

7.5.5.3. South Africa

7.5.5.3.1. Key market trends, growth factors and opportunities

7.5.5.3.2. Market size and forecast, by Products

7.5.5.3.3. Market size and forecast, by Application

7.5.5.3.4. Market size and forecast, by End User

7.5.5.4. Rest of LAMEA

7.5.5.4.1. Key market trends, growth factors and opportunities

7.5.5.4.2. Market size and forecast, by Products

7.5.5.4.3. Market size and forecast, by Application

7.5.5.4.4. Market size and forecast, by End User

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Top player positioning, 2021

9.1. Illumina Inc.

9.1.1. Company overview

9.1.2. Key Executives

9.1.3. Company snapshot

9.1.4. Operating business segments

9.1.5. Product portfolio

9.1.6. Business performance

9.1.7. Key strategic moves and developments

9.2. Agilent Technologies Inc.

9.2.1. Company overview

9.2.2. Key Executives

9.2.3. Company snapshot

9.2.4. Operating business segments

9.2.5. Product portfolio

9.2.6. Business performance

9.3. Thermo Fisher Scientific Inc.

9.3.1. Company overview

9.3.2. Key Executives

9.3.3. Company snapshot

9.3.4. Operating business segments

9.3.5. Product portfolio

9.3.6. Business performance

9.3.7. Key strategic moves and developments

9.4. PerkinElmer Inc.

9.4.1. Company overview

9.4.2. Key Executives

9.4.3. Company snapshot

9.4.4. Operating business segments

9.4.5. Product portfolio

9.4.6. Business performance

9.4.7. Key strategic moves and developments

9.5. Oxford Nanopore Technologies

9.5.1. Company overview

9.5.2. Key Executives

9.5.3. Company snapshot

9.5.4. Operating business segments

9.5.5. Product portfolio

9.5.6. Business performance

9.5.7. Key strategic moves and developments

9.6. Promega Corporation

9.6.1. Company overview

9.6.2. Key Executives

9.6.3. Company snapshot

9.6.4. Operating business segments

9.6.5. Product portfolio

9.7. PacBio

9.7.1. Company overview

9.7.2. Key Executives

9.7.3. Company snapshot

9.7.4. Operating business segments

9.7.5. Product portfolio

9.7.6. Business performance

9.7.7. Key strategic moves and developments

9.8. Bio-Rad Laboratories, Inc.

9.8.1. Company overview

9.8.2. Key Executives

9.8.3. Company snapshot

9.8.4. Operating business segments

9.8.5. Product portfolio

9.8.6. Business performance

9.9. F. Hoffmann-La Roche Ltd.

9.9.1. Company overview

9.9.2. Key Executives

9.9.3. Company snapshot

9.9.4. Operating business segments

9.9.5. Product portfolio

9.9.6. Business performance

9.10. QIAGEN

9.10.1. Company overview

9.10.2. Key Executives

9.10.3. Company snapshot

9.10.4. Operating business segments

9.10.5. Product portfolio

9.10.6. Business performance

9.10.7. Key strategic moves and development

LIST OF TABLES

TABLE 01. GLOBAL GENE EXPRESSION MARKET, BY PRODUCTS, 2021-2031 ($MILLION)

TABLE 02. GENE EXPRESSION MARKET FOR CONSUMABLE, BY REGION, 2021-2031 ($MILLION)

TABLE 03. GENE EXPRESSION MARKET FOR INSTRUMENTS, BY REGION, 2021-2031 ($MILLION)

TABLE 04. GLOBAL INSTRUMENTS GENE EXPRESSION MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 05. GLOBAL GENE EXPRESSION MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 06. GENE EXPRESSION MARKET FOR DRUG DISCOVERY, BY REGION, 2021-2031 ($MILLION)

TABLE 07. GENE EXPRESSION MARKET FOR DIAGNOSTICS, BY REGION, 2021-2031 ($MILLION)

TABLE 08. GLOBAL GENE EXPRESSION MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 09. GENE EXPRESSION MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2031 ($MILLION)

TABLE 10. GENE EXPRESSION MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2021-2031 ($MILLION)

TABLE 11. GENE EXPRESSION MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)

TABLE 12. GENE EXPRESSION MARKET, BY REGION, 2021-2031 ($MILLION)

TABLE 13. NORTH AMERICA GENE EXPRESSION MARKET, BY PRODUCTS, 2021-2031 ($MILLION)

TABLE 14. NORTH AMERICA GENE EXPRESSION MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 15. NORTH AMERICA GENE EXPRESSION MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 16. NORTH AMERICA GENE EXPRESSION MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 17. U.S. GENE EXPRESSION MARKET, BY PRODUCTS, 2021-2031 ($MILLION)

TABLE 18. U.S. GENE EXPRESSION MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 19. U.S. GENE EXPRESSION MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 20. CANADA GENE EXPRESSION MARKET, BY PRODUCTS, 2021-2031 ($MILLION)

TABLE 21. CANADA GENE EXPRESSION MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 22. CANADA GENE EXPRESSION MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 23. MEXICO GENE EXPRESSION MARKET, BY PRODUCTS, 2021-2031 ($MILLION)

TABLE 24. MEXICO GENE EXPRESSION MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 25. MEXICO GENE EXPRESSION MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 26. EUROPE GENE EXPRESSION MARKET, BY PRODUCTS, 2021-2031 ($MILLION)

TABLE 27. EUROPE GENE EXPRESSION MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 28. EUROPE GENE EXPRESSION MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 29. EUROPE GENE EXPRESSION MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 30. GERMANY GENE EXPRESSION MARKET, BY PRODUCTS, 2021-2031 ($MILLION)

TABLE 31. GERMANY GENE EXPRESSION MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 32. GERMANY GENE EXPRESSION MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 33. FRANCE GENE EXPRESSION MARKET, BY PRODUCTS, 2021-2031 ($MILLION)

TABLE 34. FRANCE GENE EXPRESSION MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 35. FRANCE GENE EXPRESSION MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 36. UK GENE EXPRESSION MARKET, BY PRODUCTS, 2021-2031 ($MILLION)

TABLE 37. UK GENE EXPRESSION MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 38. UK GENE EXPRESSION MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 39. ITALY GENE EXPRESSION MARKET, BY PRODUCTS, 2021-2031 ($MILLION)

TABLE 40. ITALY GENE EXPRESSION MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 41. ITALY GENE EXPRESSION MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 42. SPAIN GENE EXPRESSION MARKET, BY PRODUCTS, 2021-2031 ($MILLION)

TABLE 43. SPAIN GENE EXPRESSION MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 44. SPAIN GENE EXPRESSION MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 45. REST OF EUROPE GENE EXPRESSION MARKET, BY PRODUCTS, 2021-2031 ($MILLION)

TABLE 46. REST OF EUROPE GENE EXPRESSION MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 47. REST OF EUROPE GENE EXPRESSION MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 48. ASIA-PACIFIC GENE EXPRESSION MARKET, BY PRODUCTS, 2021-2031 ($MILLION)

TABLE 49. ASIA-PACIFIC GENE EXPRESSION MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 50. ASIA-PACIFIC GENE EXPRESSION MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 51. ASIA-PACIFIC GENE EXPRESSION MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 52. JAPAN GENE EXPRESSION MARKET, BY PRODUCTS, 2021-2031 ($MILLION)

TABLE 53. JAPAN GENE EXPRESSION MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 54. JAPAN GENE EXPRESSION MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 55. CHINA GENE EXPRESSION MARKET, BY PRODUCTS, 2021-2031 ($MILLION)

TABLE 56. CHINA GENE EXPRESSION MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 57. CHINA GENE EXPRESSION MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 58. AUSTRALIA GENE EXPRESSION MARKET, BY PRODUCTS, 2021-2031 ($MILLION)

TABLE 59. AUSTRALIA GENE EXPRESSION MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 60. AUSTRALIA GENE EXPRESSION MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 61. INDIA GENE EXPRESSION MARKET, BY PRODUCTS, 2021-2031 ($MILLION)

TABLE 62. INDIA GENE EXPRESSION MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 63. INDIA GENE EXPRESSION MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 64. SOUTH KOREA GENE EXPRESSION MARKET, BY PRODUCTS, 2021-2031 ($MILLION)

TABLE 65. SOUTH KOREA GENE EXPRESSION MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 66. SOUTH KOREA GENE EXPRESSION MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 67. REST OF ASIA-PACIFIC GENE EXPRESSION MARKET, BY PRODUCTS, 2021-2031 ($MILLION)

TABLE 68. REST OF ASIA-PACIFIC GENE EXPRESSION MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 69. REST OF ASIA-PACIFIC GENE EXPRESSION MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 70. LAMEA GENE EXPRESSION MARKET, BY PRODUCTS, 2021-2031 ($MILLION)

TABLE 71. LAMEA GENE EXPRESSION MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 72. LAMEA GENE EXPRESSION MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 73. LAMEA GENE EXPRESSION MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 74. BRAZIL GENE EXPRESSION MARKET, BY PRODUCTS, 2021-2031 ($MILLION)

TABLE 75. BRAZIL GENE EXPRESSION MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 76. BRAZIL GENE EXPRESSION MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 77. SAUDI ARABIA GENE EXPRESSION MARKET, BY PRODUCTS, 2021-2031 ($MILLION)

TABLE 78. SAUDI ARABIA GENE EXPRESSION MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 79. SAUDI ARABIA GENE EXPRESSION MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 80. SOUTH AFRICA GENE EXPRESSION MARKET, BY PRODUCTS, 2021-2031 ($MILLION)

TABLE 81. SOUTH AFRICA GENE EXPRESSION MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 82. SOUTH AFRICA GENE EXPRESSION MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 83. REST OF LAMEA GENE EXPRESSION MARKET, BY PRODUCTS, 2021-2031 ($MILLION)

TABLE 84. REST OF LAMEA GENE EXPRESSION MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 85. REST OF LAMEA GENE EXPRESSION MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 86. ILLUMINA INC.: KEY EXECUTIVES

TABLE 87. ILLUMINA INC.: COMPANY SNAPSHOT

TABLE 88. ILLUMINA INC.: PRODUCT SEGMENTS

TABLE 89. ILLUMINA INC.: PRODUCT PORTFOLIO

TABLE 90. ILLUMINA INC.: KEY STRATERGIES

TABLE 91. AGILENT TECHNOLOGIES INC.: KEY EXECUTIVES

TABLE 92. AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT

TABLE 93. AGILENT TECHNOLOGIES INC.: PRODUCT SEGMENTS

TABLE 94. AGILENT TECHNOLOGIES INC.: PRODUCT PORTFOLIO

TABLE 95. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES

TABLE 96. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT

TABLE 97. THERMO FISHER SCIENTIFIC INC.: PRODUCT SEGMENTS

TABLE 98. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO

TABLE 99. THERMO FISHER SCIENTIFIC INC.: KEY STRATERGIES

TABLE 100. PERKINELMER INC.: KEY EXECUTIVES

TABLE 101. PERKINELMER INC.: COMPANY SNAPSHOT

TABLE 102. PERKINELMER INC.: PRODUCT SEGMENTS

TABLE 103. PERKINELMER INC.: PRODUCT PORTFOLIO

TABLE 104. PERKINELMER INC.: KEY STRATERGIES

TABLE 105. OXFORD NANOPORE TECHNOLOGIES: KEY EXECUTIVES

TABLE 106. OXFORD NANOPORE TECHNOLOGIES: COMPANY SNAPSHOT

TABLE 107. OXFORD NANOPORE TECHNOLOGIES: PRODUCT SEGMENTS

TABLE 108. OXFORD NANOPORE TECHNOLOGIES: PRODUCT PORTFOLIO

TABLE 109. OXFORD NANOPORE TECHNOLOGIES: KEY STRATERGIES

TABLE 110. PROMEGA CORPORATION: KEY EXECUTIVES

TABLE 111. PROMEGA CORPORATION: COMPANY SNAPSHOT

TABLE 112. PROMEGA CORPORATION: PRODUCT SEGMENTS

TABLE 113. PROMEGA CORPORATION: PRODUCT PORTFOLIO

TABLE 114. PACBIO: KEY EXECUTIVES

TABLE 115. PACBIO: COMPANY SNAPSHOT

TABLE 116. PACBIO: PRODUCT SEGMENTS

TABLE 117. PACBIO: PRODUCT PORTFOLIO

TABLE 118. PACBIO: KEY STRATERGIES

TABLE 119. BIO-RAD LABORATORIES, INC.: KEY EXECUTIVES

TABLE 120. BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT

TABLE 121. BIO-RAD LABORATORIES, INC.: PRODUCT SEGMENTS

TABLE 122. BIO-RAD LABORATORIES, INC.: PRODUCT PORTFOLIO

TABLE 123. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES

TABLE 124. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT

TABLE 125. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS

TABLE 126. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO

TABLE 127. QIAGEN: KEY EXECUTIVES

TABLE 128. QIAGEN: COMPANY SNAPSHOT

TABLE 129. QIAGEN: PRODUCT SEGMENTS

TABLE 130. QIAGEN: PRODUCT PORTFOLIO

TABLE 131. QIAGEN: KEY STRATERGIES LIST OF FIGURES

FIGURE 01. GENE EXPRESSION MARKET, 2021-2031

FIGURE 02. SEGMENTATION OF GENE EXPRESSION MARKET, 2021-2031

FIGURE 03. TOP INVESTMENT POCKETS IN GENE EXPRESSION MARKET (2022-2031)

FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS

FIGURE 05. LOW BARGAINING POWER OF BUYERS

FIGURE 06. LOW THREAT OF SUBSTITUTES

FIGURE 07. LOW THREAT OF NEW ENTRANTS

FIGURE 08. LOW INTENSITY OF RIVALRY

FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALGENE EXPRESSION MARKET

FIGURE 10. GENE EXPRESSION MARKET, BY PRODUCTS, 2021(%)

FIGURE 11. COMPARATIVE SHARE ANALYSIS OF GENE EXPRESSION MARKET FOR CONSUMABLE, BY COUNTRY 2021-2031(%)

FIGURE 12. COMPARATIVE SHARE ANALYSIS OF GENE EXPRESSION MARKET FOR INSTRUMENTS, BY COUNTRY 2021-2031(%)

FIGURE 13. GENE EXPRESSION MARKET, BY APPLICATION, 2021(%)

FIGURE 14. COMPARATIVE SHARE ANALYSIS OF GENE EXPRESSION MARKET FOR DRUG DISCOVERY, BY COUNTRY 2021-2031(%)

FIGURE 15. COMPARATIVE SHARE ANALYSIS OF GENE EXPRESSION MARKET FOR DIAGNOSTICS, BY COUNTRY 2021-2031(%)

FIGURE 16. GENE EXPRESSION MARKET, BY END USER, 2021(%)

FIGURE 17. COMPARATIVE SHARE ANALYSIS OF GENE EXPRESSION MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY 2021-2031(%)

FIGURE 18. COMPARATIVE SHARE ANALYSIS OF GENE EXPRESSION MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY 2021-2031(%)

FIGURE 19. COMPARATIVE SHARE ANALYSIS OF GENE EXPRESSION MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)

FIGURE 20. GENE EXPRESSION MARKET BY REGION, 2021

FIGURE 21. U.S. GENE EXPRESSION MARKET, 2021-2031 ($MILLION)

FIGURE 22. CANADA GENE EXPRESSION MARKET, 2021-2031 ($MILLION)

FIGURE 23. MEXICO GENE EXPRESSION MARKET, 2021-2031 ($MILLION)

FIGURE 24. GERMANY GENE EXPRESSION MARKET, 2021-2031 ($MILLION)

FIGURE 25. FRANCE GENE EXPRESSION MARKET, 2021-2031 ($MILLION)

FIGURE 26. UK GENE EXPRESSION MARKET, 2021-2031 ($MILLION)

FIGURE 27. ITALY GENE EXPRESSION MARKET, 2021-2031 ($MILLION)

FIGURE 28. SPAIN GENE EXPRESSION MARKET, 2021-2031 ($MILLION)

FIGURE 29. REST OF EUROPE GENE EXPRESSION MARKET, 2021-2031 ($MILLION)

FIGURE 30. JAPAN GENE EXPRESSION MARKET, 2021-2031 ($MILLION)

FIGURE 31. CHINA GENE EXPRESSION MARKET, 2021-2031 ($MILLION)

FIGURE 32. AUSTRALIA GENE EXPRESSION MARKET, 2021-2031 ($MILLION)

FIGURE 33. INDIA GENE EXPRESSION MARKET, 2021-2031 ($MILLION)

FIGURE 34. SOUTH KOREA GENE EXPRESSION MARKET, 2021-2031 ($MILLION)

FIGURE 35. REST OF ASIA-PACIFIC GENE EXPRESSION MARKET, 2021-2031 ($MILLION)

FIGURE 36. BRAZIL GENE EXPRESSION MARKET, 2021-2031 ($MILLION)

FIGURE 37. SAUDI ARABIA GENE EXPRESSION MARKET, 2021-2031 ($MILLION)

FIGURE 38. SOUTH AFRICA GENE EXPRESSION MARKET, 2021-2031 ($MILLION)

FIGURE 39. REST OF LAMEA GENE EXPRESSION MARKET, 2021-2031 ($MILLION)

FIGURE 40. TOP WINNING STRATEGIES, BY YEAR

FIGURE 41. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 42. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 43. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 44. COMPETITIVE DASHBOARD

FIGURE 45. COMPETITIVE HEATMAP: GENE EXPRESSION MARKET

FIGURE 46. TOP PLAYER POSITIONING, 2021

FIGURE 47. ILLUMINA INC.: NET REVENUE, 2019-2021 ($MILLION)

FIGURE 48. ILLUMINA INC.: REVENUE SHARE BY SEGMENT, 2021 (%)

FIGURE 49. ILLUMINA INC.: REVENUE SHARE BY REGION, 2021 (%)

FIGURE 50. AGILENT TECHNOLOGIES INC.: NET REVENUE, 2019-2021 ($MILLION)

FIGURE 51. AGILENT TECHNOLOGIES INC.: REVENUE SHARE BY SEGMENT, 2021 (%)

FIGURE 52. AGILENT TECHNOLOGIES INC.: REVENUE SHARE BY REGION, 2021 (%)

FIGURE 53. THERMO FISHER SCIENTIFIC INC.: NET REVENUE, 2019-2021 ($MILLION)

FIGURE 54. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY SEGMENT, 2021 (%)

FIGURE 55. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY REGION, 2021 (%)

FIGURE 56. PERKINELMER INC.: NET REVENUE, 2019-2021 ($MILLION)

FIGURE 57. PERKINELMER INC.: REVENUE SHARE BY SEGMENT, 2021 (%)

FIGURE 58. PERKINELMER INC.: REVENUE SHARE BY REGION, 2019 (%)

FIGURE 59. OXFORD NANOPORE TECHNOLOGIES: NET REVENUE, 2019-2021 ($MILLION)

FIGURE 60. OXFORD NANOPORE TECHNOLOGIES: REVENUE SHARE BY SEGMENT, 2021 (%)

FIGURE 61. OXFORD NANOPORE TECHNOLOGIES: REVENUE SHARE BY REGION, 2021 (%)

FIGURE 62. PACBIO: NET REVENUE, 2019-2021 ($MILLION)

FIGURE 63. PACBIO: REVENUE SHARE BY REGION, 2021 (%)

FIGURE 64. BIO-RAD LABORATORIES, INC.: NET REVENUE, 2019-2021 ($MILLION)

FIGURE 65. BIO-RAD LABORATORIES, INC.: REVENUE SHARE BY SEGMENT, 2021 (%)

FIGURE 66. BIO-RAD LABORATORIES, INC.: REVENUE SHARE BY REGION, 2021 (%)

FIGURE 67. F. HOFFMANN-LA ROCHE LTD.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 68. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 69. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 70. QIAGEN: NET REVENUE, 2019-2021 ($MILLION)

FIGURE 71. QIAGEN: REVENUE SHARE BY SEGMENT, 2021 (%)

FIGURE 72. QIAGEN: REVENUE SHARE BY REGION, 2021 (%